Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Quality of anticoagulation control in preventing adverse events in patients with heart failure in sinus rhythm: Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction trial substudy.

Homma S, Thompson JL, Qian M, Ye S, Di Tullio MR, Lip GY, Mann DL, Sacco RL, Levin B, Pullicino PM, Freudenberger RS, Teerlink JR, Graham S, Mohr JP, Labovitz AJ, Buchsbaum R, Estol CJ, Lok DJ, Ponikowski P, Anker SD; WARCEF Investigators.

Circ Heart Fail. 2015 May;8(3):504-9. doi: 10.1161/CIRCHEARTFAILURE.114.001725. Epub 2015 Apr 7.

2.

Natural history and prognostic factors in alcoholic cardiomyopathy.

Guzzo-Merello G, Segovia J, Dominguez F, Cobo-Marcos M, Gomez-Bueno M, Avellana P, Millan I, Alonso-Pulpon L, Garcia-Pavia P.

JACC Heart Fail. 2015 Jan;3(1):78-86. doi: 10.1016/j.jchf.2014.07.014. Epub 2014 Nov 11.

PMID:
25458176
3.

Cognitive function in ambulatory patients with systolic heart failure: insights from the warfarin versus aspirin in reduced cardiac ejection fraction (WARCEF) trial.

Graham S, Ye S, Qian M, Sanford AR, Di Tullio MR, Sacco RL, Mann DL, Levin B, Pullicino PM, Freudenberger RS, Teerlink JR, Mohr JP, Labovitz AJ, Lip GY, Estol CJ, Lok DJ, Ponikowski P, Anker SD, Thompson JL, Homma S; WARCEF Investigators.

PLoS One. 2014 Nov 26;9(11):e113447. doi: 10.1371/journal.pone.0113447. eCollection 2014.

4.

Recurrent stroke in the warfarin versus aspirin in reduced cardiac ejection fraction (WARCEF) trial.

Pullicino PM, Qian M, Sacco RL, Freudenberger R, Graham S, Teerlink JR, Mann D, Di Tullio MR, Ponikowski P, Lok DJ, Anker SD, Lip GY, Estol CJ, Levin B, Mohr JP, Thompson JL, Homma S; WARCEF Investigators.

Cerebrovasc Dis. 2014;38(3):176-81. doi: 10.1159/000365502. Epub 2014 Oct 9.

5.

Warfarin and aspirin in patients with heart failure and sinus rhythm.

Homma S, Thompson JL, Pullicino PM, Levin B, Freudenberger RS, Teerlink JR, Ammon SE, Graham S, Sacco RL, Mann DL, Mohr JP, Massie BM, Labovitz AJ, Anker SD, Lok DJ, Ponikowski P, Estol CJ, Lip GY, Di Tullio MR, Sanford AR, Mejia V, Gabriel AP, del Valle ML, Buchsbaum R; WARCEF Investigators.

N Engl J Med. 2012 May 17;366(20):1859-69. doi: 10.1056/NEJMoa1202299. Epub 2012 May 2.

6.

Anticoagulation therapy in patients with heart failure due to systolic dysfunction and sinus rhythm: analysis of REDINSCOR registry.

Avellana P, Segovia J, Ferrero A, Vázquez R, Brugada J, Borrás X, Alonso-Pulpón L, Cinca J.

Rev Esp Cardiol (Engl Ed). 2012 Aug;65(8):705-12. Epub 2012 Mar 30. English, Spanish.

PMID:
22464104
7.

Genetic basis of end-stage hypertrophic cardiomyopathy.

Garcia-Pavia P, Vázquez ME, Segovia J, Salas C, Avellana P, Gómez-Bueno M, Vilches C, Gallardo ME, Garesse R, Molano J, Bornstein B, Alonso-Pulpon L.

Eur J Heart Fail. 2011 Nov;13(11):1193-201. doi: 10.1093/eurjhf/hfr110. Epub 2011 Sep 6.

8.

Long-term (5 years) effects of bosentan in patients with pulmonary arterial hypertension.

Avellana P, Segovia J, Sufrate E, Gómez-Bueno M, García-Cosío Carmena MD, García-Pavía P, Gutiérrez Landaluce C, Pérez Pereira E, Alonso-Pulpón L.

Rev Esp Cardiol. 2011 Aug;64(8):667-73. doi: 10.1016/j.recesp.2011.04.016. Epub 2011 Jun 29. English, Spanish.

9.

[Familial approach in hereditary transthyretin cardiac amyloidosis].

García-Pavía P, Avellana P, Bornstein B, Heine-Suñer D, Cobo-Marcos M, Gómez-Bueno M, Segovia J, Alonso-Pulpón LA.

Rev Esp Cardiol. 2011 Jun;64(6):523-6. doi: 10.1016/j.recesp.2010.10.018. Epub 2011 Mar 24. Spanish.

10.

Long-term follow-up of patients with indication for a implantable defibrillator for primary prevention of death.

Hadid C, Avellana P, Di Toro D, Gomez CF, Visser M, Prieto N.

Arq Bras Cardiol. 2008 May;90(5):311-5. English, Portuguese.

Supplemental Content

Loading ...
Support Center